An observational study in Systemic Sclerosis, sponsored by University Hospital, Rouen. Completed at 1 site in France. Open to participants aged 18 Years to 81 Years. Per ClinicalTrials.gov, last updated 2014-06-19.
Sponsored by University Hospital, Rouen · Observational
The aim of this prospective study is to determine prevalence and characteristics of small intestinal mucosal abnormalities in 40 patients with systemic sclerosis, using capsule endoscopy. The investigators' findings may improve management of small intestinal involvement in patients with systemic sclerosis.
688 studies on the registry are indexed under Scleroderma, Systemic; 223 are open to participants now.
This study's enrollment of 50 is below the median of 100 across 169 observational studies indexed under Scleroderma, Systemic.
Browse Scleroderma, Systemic studies →University Hospital, Rouen is the lead sponsor of 410 studies on the registry; 104 are open to participants now.
Counted across the registry records on this site, refreshed daily.
40 consecutive patients with systemic sclerosis will be included in this prospective study, without prior selection on digestive clinical manifestations
Exclusion Criteria:
Endoscopic capsule
Prevalence and characteristics of small intestinal mucosal involvement in 40 patients with systemic sclerosis
Time frame: 1 year
- to assess a correlation between the presence of small intestinal mucosal abnormalities and digestive symptoms
Time frame: 1 year
to assess a correlation between small intestinal mucosal abnormalities and nutritional status
Time frame: 1 year
to assess a correlatio between small intestinal mucosal abnormalities and extra-intestinal manifestations of systemic sclerosis
Time frame: 1 year
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Rouen